TickerGuard
Buy Day today: Neutral (57) Mixed market breadth · no major macro event
ERAS

Erasca Inc

Healthcare · Biotechnology

16.00$ +3.7% vs. previous close Closing price · As of: Oct 9, 2026

Statements

Balance Sheet

Erasca Inc (ERAS) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 435 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet ERAS
Line item Q1 20 Q2 20 Q3 20 Q4 20 Q1 21 Q2 21 Q3 21 Q4 21 Q1 22 Q2 22 Q3 22 Q4 22 Q1 23 Q2 23 Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
– – – 125 225 210 522 501 475 445 446 515 468 441 419 395 370 526 529 503 471 445 420 396 461 435
50 – – 120 214 197 492 420 403 381 366 444 398 324 306 321 307 418 330 309 315 311 300 286 254 278
-50 – – 65 170 156 446 360 333 298 219 284 273 139 113 93 77 173 69 68 70 66 70 74 47 43
50 – – 119 212 194 487 459 393 371 365 436 390 317 344 312 298 408 319 298 305 301 288 276 244 269
– – – – – – – 0.1 – 0.1 0.1 – 1.0 1.3 0.9 – 0.9 2.2 2.4 2.3 2.5 2.1 2.9 2.5 3.3 –
– – – – – – – – – – – – – – -48 – – – – – – – – – – –
– – – – 3.8 4.1 8.5 16 20 24 25 25 25 24 – – – – – – – – – – – –
– – – 239 354 360 39 45 51 50 81 103 81 78 80 79 82 75 79 79 72 73 73 71 68 73
– – – 14 11 18 20 26 21 22 28 49 26 23 27 26 30 25 30 31 25 28 29 29 27 34
– – – 0.9 0.9 1.8 1.7 0.3 0.0 0.4 2.1 1.3 6.2 7.3 7.6 7.9 4.1 8.6 4.5 9.2 4.8 4.7 4.9 5.1 5.3 5.4
– – – 0.9 1.0 1.5 1.3 4.7 4.7 2.3 4.3 23 3.4 2.6 3.7 2.0 2.6 2.1 2.4 0.5 2.3 1.7 3.0 1.0 2.2 2.0
50 – – -114 -129 -150 483 457 425 395 -346 -481 -514 363 -576 317 288 451 450 423 400 372 348 325 394 362
– – – -115 -133 -162 -208 -238 -275 -310 -346 -481 -514 -546 -576 -606 -641 -704 -735 -768 -799 -833 -863 -892 -1,076 -1,120
73 75 75 73 75 75 79 95 96 96 97 102 120 120 120 121 121 174 226 234 283 283 284 284 304 311

Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?